



# PRO INSTRUMENTS USED IN STUDIES OF PULMONARY HYPERTENSION SINCE 1960

### Alison Martin<sup>1</sup> <sup>1</sup>Crystallise Ltd, Essex, UK alison.martin@crystallise.com

### **Objectives**

To create an evidence map of the different patient-reported outcome instruments used in studies of patients with skin cancer, the geographical settings in which these studies were conducted and the interventions assessed.

### Methods

We searched the heoro.com database (www.heoro.com) for PRO studies on skin cancer published between 1960 and May 15 2017, and analysed the abstracts identified by the search to determine the different PRO instruments cited across the range of geographical locations and interventions. We presented the findings as an evidence map.

#### Map of type of skin cancer by PRO instrument

AKQoL

aBCCdex

Results	Map of studies by publication date
---------	------------------------------------

Year	1960-1999	2000-2004	2005-2010	2011-2015	2015-2017				
Abstracts	6	17	13	29	14				
ADQI – Australian BPI – Brief Pain I BSI – Brief Symp CSQ – Cassileth DLQI – Dermatol DQOL – Dermatol DQOL – Dermatol EORTC QLQ-C3 Treatment of Can EORTC- melano EQ-5D – EuroQo FACT-BR – Func FACT-BR – Func FACT-BR – Func FACT-BR – FACT- FACT-G – FACT- FACT-G – FACT- FSCI – Facial Ski GHS – Global He HADS – Hospital HALex – Health I IES – Impact of E LCWS – Lerman'	otom Inventory Scar Questionnaire ogy Life Quality Ind ology Quality of Life <b>0</b> – European Orga ncer Quality of Life ( ma – EORTC mela I Questionnaire tional Assessment CT- Biologic Respo General Melanoma in Cancer Index ealth Status Anxiety and Depre Utility Index	e dex e Scales anization for Researc Core module anoma module of Cancer Therapy - onse Modifiers	PAIS-SR report POSAS - POSHN - POMS - QWB-SA QWB-SA RSES - RSCL - SF-12 - SF-36 - SF-36 - SCQOLI SEBI - S SCQOLI SEBI - S STAI - S TSQM - UKSIP - VAS - Vi VSPSQ - VSS - Va	<ul> <li>Patient /Observer Solution</li> <li>Patient Outcomes of Profile Of Mood State</li> <li>Quality of Well-Bei</li> <li>Rosenberg Self-Estee</li> <li>Rotterdam Symptom Of Short Form 12 items</li> <li>Short Form 36 items</li> <li>in Cancer Index</li> <li>Skin Cancer Quality</li> <li>T – Skin Cancer Quality</li> <li>T – Skin</li></ul>	of Life ity of Life Impact Tool naviour Inventory n Questionnaire for Medi				

FACT-

BRM

FACT-G

FACT-M

FSC

ADQIBPIBSICSQDLQIDQOLEORTCEORTC-EQ-5DFACT-BRQLQ-C30melanoma

										<b>t</b> - <b>t</b>									
Any /other	0	1	1	0	0	0		1	0	1		0	0	1	0	2	2	0	0
Melanoma	0	0	0	1	2	1		0	0	12		1	2	0	1	(	)	4	0
Squamou s cell	0	1	0	0	0	0		1	0	1		0	0	0	0	(	)	0	0
Basal cell	1	0	0	0	0	0		0	0	1		0	0	0	0	(	)	0	0
Non- melanoma	0	0	0	0	0	0		5	1	0		0	0	0	0		2	0	2
	GHS	GSI	HADS	HALex	IES	6 LC	CWS	MCSDS	MQLQ	PAIS-S	SR	POSAS	POSH	N PO	MS QWE	B-SA	RSCL		RSES
Any /other	1	0	0	0	0		0	0	1	0		1	0	0	) (	)	0		0
Melanoma	1	1	3	1	1		0	1	0	1		0	0	1		-	1		0
Squamous cell	1	0	0	0	0		0	0	0	0		0	0	(	) (	)	0		0
Basal cell	1	0	0	0	0		0	0	0	0		0	0	0	) (	)	0		0
Non- melanoma	0	0	0	0	0		1	0	0	0		0	1	(	) (	)	0		1
	SF-12	SF-36	SCI	SCQoL	. SCQ	OLIT	SEBI	SKINDE	X ST	AI TS	<b>SQM</b>	UKSIF	<b>&gt;</b> V	AS	VSPSQ	VSS	W	OC	Unclear
Any /other	0	1	1	0		1	1	1	1	L	0	1		2	1	1		0	9
Melanoma	0	5	0	0		1	0	1	2	2	0	0		0	0	0		1	12
Squamous cell	0	0	1	0		0	0	2	C	)	1	0		2	0	0		0	2
Basal cell	1	0	1	0		0	0	2	C	)	1	0		2	0	0		0	8
Non- melanoma	2	3	3	1		2	0	2	C	)	0	0		1	0	1		0	1

#### Map of geographical location by intervention

	Surgery	Dabrafenib	Dacarbazine	Denileukin	Fotemustine	Imiquimod	Interferon	Intetumumab	Temozolamide	Trametinib	Chemo- therapy	Electro- chemotherapy	Laser therapy	Photo- dynamic therapy	Radio- ablation	Immuno- therapy	Prevention/ surveillance	Other /none
Australia	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2
Austria	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Belgium	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0
Canada	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1
Denmark	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Finland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Germany	0	0	0	0	0	0	0	0	0	1	2	0	0	0	0	0	0	1
India	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
International	0	1	1	0	1	0	1	0	1	1	0	0	0	0	0	0	3	3
Italy	1	0	0	0	0	0	0	0	0	0	1	1	0	1	0	1	0	1
Japan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Netherlands	1	0	0	0	0	1	0	0	0	0	0	0	0	2	0	0	0	1
New Zealand	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
Norway	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Spain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
Sweden	1	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0	0	0
Switzerland	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
Taiwan	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
UK	3	0	2	0	0	1	2	0	1	0	1	0	1	2	0	0	1	1
USA	9	0	1	1	0	0	2	1	0	0	1	0	0	0	0	0	5	6
Unknown	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Numbers refer to number of studies identified for each category. Where a study is set in two or three locations, these are all listed separately. Studies set in five or more jurisdictions, or systematic reviews are classified as International. Studies are mapped to all relevant subcategories.

## Conclusions

A wide range of PRO tools have been used in studies of skin cancer from a wide range of locations, but only six tools and three countries were cited in five or more abstracts.

**Crystallise Ltd.** Unit 21 Thames Enterprise Centre, Thames Industrial Park, East Tilbury, Essex RM18 8RH , UK Tel: +44 (0)1375 488020

For a copy of this poster or the interactive evidence map, email: alison.martin@crystallise.com



Presented at the ISPOR 20<sup>th</sup> European Congress 4-8November 2017, Glasgow, Scotland

www.crystallise.com www.heoro.com